Yasuo Miyoshi
Overview
Explore the profile of Yasuo Miyoshi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
174
Citations
2969
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Nagahashi M, Miyoshi Y
Int J Mol Sci
. 2024 Mar;
25(6).
PMID: 38542328
In recent years, newly emerging therapies, such as immune checkpoint inhibitors and antibody-drug conjugates, have further improved outcomes for breast cancer patients. However, recurrent and metastatic breast cancer often eventually...
12.
Tsuchida Y, Niikura N, Chishima T, Mizuno M, Kawate T, Fuchikami H, et al.
Breast Cancer
. 2024 Mar;
31(3):401-408.
PMID: 38451415
Purpose: Oncotype DX® is a frequently used multigene assay for hormone receptor-positive breast cancers. However, limited evidence is available regarding its application in Japan owing to the lack of insurance...
13.
Fukui R, Watanabe T, Morimoto K, Fujimoto Y, Nagahashi M, Ishikawa E, et al.
Breast Cancer
. 2024 Mar;
31(3):536-538.
PMID: 38433180
No abstract available.
14.
Tokunaga E, Miyoshi Y, Dozono K, Kawaguchi T, Toi M
Oncologist
. 2023 Nov;
29(3):e319-e329.
PMID: 37971418
Background: Established prognostic factors for treatment response to cyclin-dependent kinases 4 and 6 inhibitors are currently lacking. We aimed to investigate the relationship of pretreatment neutrophil-to-lymphocyte ratio (NLR) and absolute...
15.
Bun A, Nagahashi M, Kuroiwa M, Komatsu M, Miyoshi Y
Breast Cancer Res Treat
. 2023 Sep;
202(3):575-583.
PMID: 37733188
Purpose: Eribulin is a unique anti-cancer drug which can improve overall survival (OS) of patients with metastatic breast cancer (MBC), probably by modulating the tumor immune microenvironment. The aim of...
16.
Masuda H, Tanabe Y, Sakai H, Matsumoto K, Shimomura A, Doi M, et al.
Breast
. 2023 Jul;
71:22-28.
PMID: 37459790
Background: Abemaciclib-induced diarrhea (AID) impairs quality of life (QOL) and treatment adherence in patients with breast cancer. Supportive treatment with loperamide is associated with constipation. We hypothesized that probiotics and...
17.
Wu R, Oshi M, Asaoka M, Yan L, Benesch M, Khoury T, et al.
Ann Surg
. 2023 Jun;
278(4):587-597.
PMID: 37318852
Objective: To investigate the clinical relevance of intratumoral tumor infiltrating lymphocytes (TILs) in breast cancer as measured by computational deconvolution of bulk tumor transcriptomes. Summary Background Data: Commonly assessed TILs,...
18.
Fukui R, Watanabe T, Morimoto K, Fujimoto Y, Nagahashi M, Ishikawa E, et al.
Breast Cancer
. 2023 Apr;
30(5):703-713.
PMID: 37115435
Background: The reason for the poor prognosis of estrogen receptor (ER) + /human epidermal growth factor receptor 2 (HER2)- breast cancer patients with high levels of tumor-infiltrating lymphocytes (TILs) is...
19.
Andre F, Park Y, Kim S, Takano T, Im S, Borges G, et al.
Lancet
. 2023 Apr;
401(10390):1773-1785.
PMID: 37086745
Background: In the single-arm, phase 2 DESTINY-Breast01 trial, trastuzumab deruxtecan showed robust activity in patients with HER2-positive metastatic breast cancer who were refractory or resistant to trastuzumab emtansine; a population...
20.
Nagahashi M, Ling Y, Toshikawa C, Hayashida T, Kitagawa Y, Futamura M, et al.
Breast Cancer
. 2023 Mar;
30(4):584-595.
PMID: 36930419
Background: Next-generation sequencing (NGS) has enabled comprehensive genomic profiling to identify gene alterations that play important roles in cancer biology. However, the clinical significance of these genomic alterations in triple-negative...